Heart FailureRoyal Devon and Exeter HospitalFrailtyHFpEFNT-proBNP >2000 ng/LHFrEF
… with NT-proBNP >2000 ng/L and HFpEF attending the Rapid Access Heart Failure clinic (HF Hub)Methods A retrospective audit was conducted usin…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 55 of 2459nerandomilastnintedanibSSc-ILDPrednisonemycophenolaterituximabtocilizumab
…in 4 (17.4%), 7 (28.0%) and 11 (40.7%) patients in the placebo, nerandomilast 9 mg and 18 mg BID groups, respectively. Rates of treatment dis…
CAB-LAGonorrhoeaChlamydiaHIVcabotegravirCBSPrEPPrEP-experienced
…ve access and persistence. Long-acting injectable cabotegravir (CAB-LA) has recently been introduced in some Italian clinical centres,…
community-acquired pneumoniaamoxicillin-clavulanateamoxicillin
…he effectiveness of amoxicillin and amoxicillin-clavulanate for community-acquired pneumonia in children and adults.Design Systematic review and meta-analys…
PsAPsOIL-12/23 inhibitorspsoriatic arthritisinterleukin (IL)-17 inhibitors
…py was significantly associated with a reduced risk of incident PsA compared with TNF inhibitors.…
Cardiovascular diseaseCVD
…Objective Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality w…
hyperglycaemiaSCAMPmetabolic acidosis
…ity of extremely premature neonates receiving SCAMP experienced hyperglycaemia. Lower rates of metabolic acidosis were observed among patients…
Attention deficit hyperactivity disordermethylphenidateNCT06906328ADHDMPHCognitive remediation therapy
…Introduction Attention deficit hyperactivity disorder (ADHD) affects 2.5% of adults in the general population, compar…
brigatinibosimertiniboligometastatic NSCLCstage IV lung cancerstage IV NSCLCNational Institute for Clinical Excellencesystemic therapyNICENSCLCSTS
…-rearranged metastatic NSCLC, median PFS reached 66 months with brigatinib, followed by brigatinib plus LCT (radiation and/or surgery), co…